

Product information



Information about other products is available at: www.IBL-America.com

ImmunoGuide®

Instructions for Use

Rituximab ELISA (mAb-based)

Enzyme immunoassay for the specific determination
of free Rituximab in serum and plasma

REF: TM09016



12X8



2-8°C

For Research Use Only - Not for Use in Diagnostic Procedures

Manufactured for
Immuno-Biological Laboratories Inc. (IBL-America)

8201 Central Avenue NE,
Suite P Minneapolis,
MN 55432 USA

Tel: 763-780-2955 Toll Free: 1-888-523-1246

www.ibl-america.com

| <u>Contents</u> | <u>Page</u> |
|--|--------------------|
| 1. Intended Use | 2 |
| 2. Summary and Explanation | 2 |
| 3. Principle of the Test | 2 |
| 4. Warnings and Precautions | 2 |
| 5. Storage and Stability of the Kit | 3 |
| 6. Specimen Collection, Handling and Storage | 3 |
| 7. Contents of the Kit | 4 |
| 8. Materials Required but not Supplied | 4 |
| 9. Procedure Notes | 4 |
| 10. Pre-Test Setup Instructions | 5 |
| 10.1. Preparation of Components | 5 |
| 10.2. Dilution of Standards and Samples | 6 |
| 11. Test Procedure | 6 |
| 11.1. General Remarks | 6 |
| 11.2. Assay Procedure | 7 |
| 11.3. Quality Control | 8 |
| 11.4. Calculation of Results | 8 |
| 12. Assay characteristics | 9 |
| 12.1. Specificity | 9 |
| 12.2. Sensitivity | 9 |
| 12.3. Precision | 10 |
| 12.4. Recovery | 10 |
| 13. Automation | 10 |
| 14. References | 10 |

1. INTENDED USE

Enzyme immunoassay for the specific determination of free Rituximab in serum and plasma. For research use only - not for use in diagnostic procedures.

2. SUMMARY AND EXPLANATION

The drug Rituximab (trade name Rituxan[®] and Mabthera[®]) is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is a glycosylated IgG1 kappa immunoglobulin containing murine light- and heavy-chain variable region sequences (Fab domain) and human constant region sequences (Fc domain). Rituximab is composed of 1,328 amino acids and has an approximate molecular weight of 144 kD. Rituximab has a high binding affinity for the CD20 antigen.

The specificity of this testsystem is achieved by using a monoclonal antibody (clon 9D5b) for the coating of the microtiter plate. This antibody is specific for Rituximab only (regardless whether Rituxan[®] and Mabthera[®]) and does not cross react with other CD20 catchers.

3. PRINCIPLE OF THE TEST

This ELISA is based on Rituximab-specific mouse monoclonal antibody (catcher Ab, *ImmunoGuide* clone IG-9D5b). Diluted standards and samples are incubated in the microtiter plate coated with IG-9D5b mAb. After incubation, the wells are washed. A horseradish peroxidase (HRP)-conjugated anti-human IgG monoclonal antibody is added and binds to the Fc part of Rituximab. Following incubation, wells are washed and the bound enzymatic activity is detected by addition of chromogen-substrate. The colour developed is proportional to the amount of Rituximab in the sample or standard. Results of samples can be determined by using the standard curve. Binding of Rituximab to the solid phase, pre-coated with 9D5b, is inhibited by recombinant human CD20 protein. Therefore, the *ImmunoGuide* Rituximab ELISA (mAb-Based) measures the free form of Rituximab.

4. WARNINGS AND PRECAUTIONS

1. Before starting the assay, read the instructions completely and carefully. Use the valid version of the package insert provided with the kit. Be sure that everything is understood. For further information (clinical background, test performance, automation protocols, alternative applications, literature, etc.) please refer to the local distributor.
2. In case of severe damage of the kit package, please contact **IBL-America** or your supplier in writing, latest one week after receiving the kit. Do not use damaged components in test runs, but keep safe for complaint related issues.
3. Obey lot number and expiry date. Do not mix reagents of different lots. Do not use expired reagents.

4. Follow good laboratory practice and safety guidelines. Wear lab coats, disposable latex gloves and protective glasses where necessary.
5. Reagents of this kit containing hazardous material may cause eye and skin irritations. See MATERIALS SUPPLIED and labels for details.
6. Chemicals and prepared or used reagents have to be treated as hazardous waste according the national biohazard safety guidelines or regulations.
7. Avoid contact with Stop solution. It may cause skin irritations and burns.
8. If any component of this kit contains human serum or plasma it is indicated and if so, it have been tested and were found to be negative for HIV I/II, HBsAg and HCV. However, the presence of these or other infectious agents cannot be excluded absolutely and therefore reagents should be treated as potential biohazards in use and for disposal.
9. Some reagents contain preservatives. In case of contact with eyes or skin, flush immediately with water.

5. STORAGE AND STABILITY OF THE KIT

The kit is shipped at ambient temperature and should be stored at 2-8°C. Keep away from heat or direct sun light. The storage and stability of specimen and prepared reagents is stated in the corresponding chapters. The microtiter strips are stable up to the expiry date of the kit in the broken, but tightly closed bag when stored at 2-8°C.

6. SPECIMEN COLLECTION, HANDLING AND STORAGE

Serum, Plasma (EDTA, Heparin)

The usual precautions for venipuncture should be observed. It is important to preserve the chemical integrity of a blood specimen from the moment it is collected until it is assayed. Do not use grossly hemolytic, icteric or grossly lipemic specimens. Samples appearing turbid should be centrifuged before testing to remove any particulate material.

| | | | |
|------------|-------|-------------------|--|
| Storage: | 2-8°C | ≤-20°C (Aliquots) | Keep away from heat or direct sun light Avoid repeated freeze-thaw cycles |
| Stability: | 3 d | 6 mon | |

7. CONTENTS OF THE KIT

| QUANTITY | COMPONENT |
|------------|---|
| 1 x 12 x 8 | Microtiter ELISA Plate Break apart strips coated with anti-Rituximab monoclonal antibody. |
| 5 x 0.5 mL | Rituximab Standards A-E, Concentrate (10X) 2000; 600; 200; 60; and 0 ng/mL Used for construction of the standard curve. Contains Rituximab, proteins, preservative and stabilizer. |
| 1 x 12 mL | Assay Buffer Blue colored. Ready to use. Contains proteins and preservative. |
| 1 x 60 mL | Dilution Buffer, Concentrate (5X) Contains orange dye, proteins and preservative. |
| 1 x 12 mL | Enzyme Conjugate Red colored. Ready to use. Contains horseradish peroxidase(HRP)-conjugated anti-human IgG mouse monoclonal antibody, Proclin [®] and stabilizers. |
| 1 x 12 mL | TMB Substrate Solution Ready to use. Contains 3,3',5,5'-Tetramethylbenzidine (TMB). |
| 1 x 12 mL | Stop Solution Ready to use. 1 N Hydrochloric acid (HCl). |
| 1 x 50 mL | Wash Buffer, Concentrate (20x) Contains buffer, Tween [®] 20 and Kathon [™] . |
| 2 x 1 | Adhesive Seal For sealing microtiter plate during incubation. |

8. MATERIALS REQUIRED BUT NOT SUPPLIED

1. Micropipettes (< 3% CV) and tips to deliver 5-1000 µL.
2. Bidistilled or deionised water and calibrated glasswares (e.g. flasks or cylinders).
3. Wash bottle, automated or semi-automated microtiter plate washing system.
4. Microtiter plate reader capable of reading absorbance at 450 nm (reference wavelength at 600-650 nm is optional).
5. Absorbent paper towels, standard laboratory glass or plastic vials, and a timer.

9. PROCEDURE NOTES

1. Any improper handling of samples or modification of the test procedure may influence the results. The indicated pipetting volumes, incubation times, temperatures and pre-treatment steps have to be performed strictly according to the instructions. Use calibrated pipettes and devices only.
2. Once the test has been started, all steps should be completed without interruption. Make sure that required reagents, materials and devices are prepared readily at the appropriate time. Allow all reagents and specimens to reach room temperature (20-25 °C) and gently swirl each vial of liquid reagent and sample before use. Mix reagents without foaming.
3. Avoid contamination of reagents, pipettes and wells/tubes. Use new disposable plastic pipette tips for each reagent, standard or specimen. Do not interchange the caps of vials. Always cap not used vials. Do not reuse wells or reagents.
4. Use a pipetting scheme to verify an appropriate plate layout.
5. Incubation time affects results. All wells should be handled in the same order and time sequences. It is recommended to use an 8-channel Micropipettor for pipetting of solutions in all wells.
6. Microplate washing is important. Improperly washed wells will give erroneous results. It is recommended to use a multichannel pipette or an automatic microplate washing system. Do not allow the wells to dry between incubations. Do not scratch coated wells during rinsing and aspiration. Rinse and fill all reagents with care. While rinsing, check that all wells are filled precisely with Wash Buffer, and that there are no residues in the wells.
7. Humidity affects the coated wells. Do not open the pouch until it reaches room temperature. Unused wells should be returned immediately to the resealed pouch including the desiccant.

10. PRE-TEST SETUP INSTRUCTIONS

10.1. Preparation of Components*

| Dilute/ dissolve | Component | | Diluent | Relation | Remarks | Storage | Stability |
|---------------------|-----------------|-----------------|--------------------|----------|---|---------|-----------|
| 10 mL | Wash Buffer | up to 200 mL | Distilled Water | 1:20 | Warm up at 37°C to dissolve crystals. Mix vigorously. | 2-8 °C | 4 w |
| 10 mL | Dilution Buffer | up to 50 mL | Distilled Water | 1:5 | | 2-8 °C | 4 w |


* Prepare Wash and Dilution Buffers before starting the assay procedure.

10.2. Dilution of Standards and Samples

The dilutions depicted below are examples of how to obtain final dilutions for standards and samples. Standards and samples should be properly diluted as homogenous mixture before starting the assay procedure. It is recommended mixing the standards and samples well to homogenous solution at each dilution step. We are recommending that each laboratory determines the best initial dilution for their samples in order to minimize retesting.

1. 10 μL of standard or sample added to 90 μL of 1X dilution buffer, giving the total volume of 100 μL and a dilution of 1:10.
2. 10 μL of 1:10 diluted sample added to 1990 μL of 1X dilution buffer, giving the total volume of 2000 μL and a final dilution of 1:2000. This 2nd dilution step should not be done with the standards!
3. Samples with a drug concentration above the measuring range should be rated as “>highest standard”. The result should not be extrapolated. The sample in question should be further diluted with 1X Dilution Buffer and then retested.

Standard/Sample Dilution



11. TEST PROCEDURE

11.1. GENERAL REMARKS

11.1.1. Before performing the assay, samples and assay kit should be brought to room temperature (about 30 minutes beforehand) and ensure the homogeneity of the solution.

11.1.2. All Standards should be run with each series of unknown samples.

11.1.3. Standards should be subject to the same manipulations and incubation times as the samples being tested.

11.1.4. All steps of the test should be completed without interruption.

11.1.5. Use new disposable plastic pipette tips for each reagent, standard or specimen in order to avoid cross contamination.

11.1.6. The total pipetting time needed for dispensing all samples into the wells should not exceed 5 minutes. If this is difficult to achieve the samples should be pre-dispensed in a separate neutral polypropylene microplate and then transferred into the reaction ELISA plate by a multi channel pipette.

11.2. ASSAY PROCEDURE

| | |
|-----|--|
| 1. | Pipette 100 μL of Assay Buffer into each of the wells to be used. |
| 2. | <p>Pipette 75 μL of each 1:10 Diluted Standard, and 1:2000 Diluted Samples into the respective wells of the microtiter plate. Bubble formation during the pipetting of standards and samples must be avoided.</p> <p><u>Wells</u></p> <p>A1: Standard A B1: Standard B C1: Standard C D1: Standard D E1: Standard E F1 and so on: Samples (Serum/Plasma)</p> |
| 3. | Cover the plate with adhesive seal. Shake plate carefully by tapping several times. Incubate the plate on a bench top for 60 min at room temperature (RT, 20-25°C). |
| 4. | Remove adhesive seal. Aspirate or decant the incubation solution. Wash the plate 4 X 350 μL of Diluted Wash Buffer per well. Remove excess solution by tapping the inverted plate on a paper towel. |
| 5. | Pipette 100 μL of Enzyme Conjugate (HRP-anti human IgG mAb) into each well. |
| 6. | Cover plate with adhesive seal. Shake plate carefully by tapping several times. Incubate the plate on a bench top for 30 min at RT. |
| 7. | Remove adhesive seal. Aspirate or decant the incubation solution. Wash the plate 4 X 350 μL of Diluted Wash Buffer per well. Remove excess solution by tapping the inverted plate on a paper towel. |
| 8. | Pipette 100 μL of Ready-to-Use TMB Substrate Solution into each well. |
| 9. | Incubate 10 min at RT. Avoid exposure to direct sunlight. |
| 10. | Stop the substrate reaction by adding 100 μL of Stop Solution into each well. Briefly mix contents by gently shaking the plate. Color changes from blue to yellow. |
| 11. | Measure optical density (OD) with a photometer at 450 nm (Reference at OD620 nm is optional) within 15 min after pipetting the Stop Solution. |

11. 3. QUALITY CONTROL

The test results are only valid if the test has been performed following the instructions. Moreover the user must strictly adhere to the rules of GLP (Good Laboratory Practice) or other applicable standards/laws. All standards/controls must be found within the acceptable ranges as stated above and/or label. If the criteria are not met, the run is not valid and should be repeated. In case of any deviation, the following technical issues should be reviewed: Expiration dates of (prepared) reagents, storage conditions, pipettes, devices, incubation conditions and washing methods.


11. 4. CALCULATION OF RESULTS

A standard curve should be constructed using the standard concentration (X-axis) versus the OD450 (or OD450/620) values (Y-axis). This can be done manually using graph paper or with a computer program. Concerning the data regression by computer, it is recommended to primarily use the "4 Parameter Logistic (4PL)" or alternatively the "point-to-point calculation". In case of manual plot there are 2 options: Semilog graph (see Fig. A) or linear graph (see Fig. B). Semilog graph paper is available at <http://www.papersnake.com/logarithmic/semilogarithmic/>. The concentration of the samples can be read from this standard curve as follows. Using the absorbance value for each sample, determine the corresponding concentration of the drug from the standard curve. This value always has to be multiplied by the individual dilution factor (usually 2000). If any diluted sample is reading greater than the highest standard, it should be further diluted appropriately with 1X Dilution Buffer and retested. Also this second dilution has to be used for calculation of the final result. We are recommending that each laboratory determines the best initial dilution for their samples in order to minimize retesting.

Typical Calibration Curve

(All steps were performed at 23°C. Just an example. Do not use it for calculation!)

| 1:10 Diluted Standard | A | B | C | D | E |
|-----------------------|-------|-------|-------|-------|-------|
| Concentration (ng/mL) | 200 | 60 | 20 | 6 | 0 |
| Mean OD450/620 nm | 2.640 | 1.308 | 0.502 | 0.204 | 0.018 |



12. ASSAY CHARACTERISTICS

12.1. SPECIFICITY

There is no cross reaction with any other proteins present in native human serum. A screening test was performed with 48 different native human sera. All produced OD_{450/620 nm} values less than the mean OD (0.204) of standard D (6 ng/mL). In addition, binding of Rituximab is inhibited by recombinant human CD20 protein. Therefore, the *ImmunoGuide* Rituximab ELISA (mAb-Based) measures the biologically active free form of Rituximab, i.e. not pre-occupied by human CD20 antigen. No cross reaction was observed with sera spiked with the other therapeutic antibodies including Infliximab, Adalimumab, Golimumab, Etanercept, Bevacizumab and Trastuzumab at concentrations up to 500 µg/mL.

12.2. SENSITIVITY

The lowest detectable level that can be clearly distinguished from the zero standard is 2 ng/mL (zero standard +2SD read from the curve) under the above-described conditions. Analytical sensitivity is 2 ng/mL, and corresponding to the detection limit (limit of quantification) of 4 µg/mL for undiluted clinical samples because the serum or plasma samples are instructed to be diluted at 1:2000 before starting the assay.

12.3. PRECISION

Intra-assay CV: <10%.

Inter-assay CV: <10%.

12.4. RECOVERY

Recovery rate was found to be >95% with native human serum and plasma samples when spiked with exogenous Rituximab.

13. AUTOMATION

The *ImmunoGuide* Rituximab ELISA (mAb-based) is suitable also for being used by an automated ELISA processor.

14. REFERENCES

1. Assouline S, Buccheri V, Delmer A, Gaidano G, McIntyre C, Brewster M, Catalani O, Hourcade-Potelleret F, Sayyed P, Badoux X. Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia. *Br J Clin Pharmacol.* 2015;80(5):1001-9
2. Salar A, Avivi I, Bittner B, Bouabdallah R, Brewster M, Catalani O, Follows G, Haynes A, Hourcade-Potelleret F, Janikova A, Larouche JF, McIntyre C, Pedersen M, Pereira J, Sayyed P, Shpilberg O, Tumen G. Comparison of subcutaneous versus intravenous administration of rituximab as maintenance treatment for follicular lymphoma: results from a two-stage, phase IB study. *J Clin Oncol.* 2014;32(17):1782-91.
3. Compagno N, Cinetto F, Semenzato G, Agostini C. Subcutaneous immunoglobulin in lymphoproliferative disorders and rituximab-related secondary hypogammaglobulinemia: a single-center experience in 61 patients. *Haematologica.* 2014;99(6):1101-6.
4. Davies A, Merli F, Mihaljevic B, Siritanaratkul N, Solal-Céligny P, Barrett M, Berge C, Bittner B, Boehnke A, McIntyre C, Macdonald D. Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study. *Lancet Oncol.* 2014;15(3):343-52.
5. Bittner B, Richter WF, Hourcade-Potelleret F, Herting F, Schmidt J. Non-clinical pharmacokinetic/pharmacodynamic and early clinical studies supporting development of a novel subcutaneous formulation for the monoclonal antibody rituximab. *Drug Res (Stuttg).* 2014;64(11):569-75.
6. Mao CP, Brovarney MR, Dabbagh K, Birnböck HF, Richter WF, Del Nagro CJ. Subcutaneous versus intravenous administration of rituximab: pharmacokinetics, CD20 target coverage and B-cell depletion in cynomolgus monkeys. *PLoS One.* 2013 Nov 12;8(11):e80533. doi: 10.1371/journal.pone.0080533
7. Barth MJ, Goldman S, Smith L, Perkins S, Shiramizu B, Gross TG, Harrison L, Sanger W, Geyer MB, Giulino-Roth L, Cairo MS. Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: a Children's Oncology Group report. *Br J Haematol.* 2013;162(5):678-83.
8. Brown JR, Messmer B, Werner L, Davids MS, Mikler E, Supko JG, Fisher DC, LaCasce AS, Armand P, Jacobsen E, Dalton V, Tesar B, Fernandes SM, McDonough S, Ritz J, Rassenti L, Kipps TJ, Neuberger D, Freedman AS. A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. *Haematologica.* 2013;98(6):964-70.
9. Gao B, Yeap S, Clements A, Balakrishnar B, Wong M, Gurney H. Evidence for therapeutic drug monitoring of targeted anticancer therapies. *J Clin Oncol.* 2012;30(32):4017-25.

10. Jäger U, Fridrik M, Zeitlinger M, Heintel D, Hopfinger G, Burgstaller S, Mannhalter C, Oberaigner W, Porpaczy E, Skrabs C, Einberger C, Drach J, Raderer M, Gaiger A, Putman M, Greil R; Arbeitsgemeinschaft Medikamentöse Tumortherapie (AGMT) Investigators. Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response. *Haematologica*. 2012;97(9):1431-8.
11. McDonald V1, Manns K, Mackie IJ, We are recommending that each laboratory determines the best initial dilution for their samples in order to minimize retesting., Scully MA. Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura. *J Thromb Haemost*. 2010;8(6):1201-8.
12. Tobinai K, Igarashi T, Itoh K, Kobayashi Y, Taniwaki M, Ogura M, Kinoshita T, Hotta T, Aikawa K, Tsushita K, Hiraoka A, Matsuno Y, Nakamura S, Mori S, Ohashi Y; IDEC-C2B8 Japan Study Group. Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma. *Ann Oncol*. 2004;15(5):821-30.
13. Alexandru S, Gonzalez E, Grande C, Hernandez A, Morales E, Praga M, Andres A, Morales JM. Monotherapy rapamycin in renal transplant recipients with lymphoma successfully treated with rituximab. *Transplant Proc*. 2009;41(6):2435-7.
14. Miranda-Hernández MP, López-Morales CA, Ramírez-Ibáñez ND, Piña-Lara N, Pérez NO, Molina-Pérez A, Revilla-Beltri J, Flores-Ortiz LF, Medina-Rivero E. Assessment of physicochemical properties of rituximab related to its immunomodulatory activity. *J Immunol Res*. 2015;2015:910763. doi: 10.1155/2015/910763
15. Mazilu D, Opreș D, Gainaru C, Iliuta M, Apetrei N, Luca G, Borangiu A, Gudu T, Peltea A, Groseanu L, Constantinescu C, Saulescu I, Bojinca V, Balanescu A, Predeteanu D, Ionescu R. Monitoring drug and antidrug levels: a rational approach in rheumatoid arthritis patients treated with biologic agents who experience inadequate response while being on a stable biologic treatment. *Biomed Res Int*. 2014;2014:702701. doi: 10.1155/2014/702701.
16. Mok CC. Rituximab for the treatment of rheumatoid arthritis: an update. *Drug Des Devel Ther*. 2013;8:87-100.
17. Chen K, Page JG, Schwartz AM, Lee TN, DeWall SL, Sikkema DJ, Wang C. False-positive immunogenicity responses are caused by CD20+ B cell membrane fragments in an anti-ofatumumab antibody bridging assay. *J Immunol Methods*. 2013;394(1-2):22-31.
18. Schmidt E, Hennig K, Mengede C, Zillikens D, Kromminga A. Immunogenicity of rituximab in patients with severe pemphigus. *Clin Immunol*. 2009;132(3):334-41.
19. Annibali O, Chiodi F, Sarlo C, Cortes M, Quaranta-Leoni FM, Quattrocchi C, Bianchi A, Bonini S, Avvisati G Rituximab as Single Agent in Primary MALT Lymphoma of the Ocular Adnexa. *Biomed Res Int*. 2015;2015:895105. doi: 10.1155/2015/895105.
20. Kidd DP. Rituximab is effective in severe treatment-resistant neurological Behçet's syndrome. *J Neurol*. 2015 Sep 26. (Epub ahead of print).